Medical equipment is not stand-alone hardware anymore. They are becoming software-controlled, networked and interconnected with cloud platforms, hospital IT systems and remote update systems in the US market. This has radically altered the FDA’s view on the safety of devices. Cybersecurity has become a patient safety concern, rather than a non-technical option.
Consequently, the selection of the appropriate medical device security company has now become a critical choice among the manufacturers who want to have their medical devices cleared or approved by the FDA. FDA reviewers do not examine design-time controls or theoretical threat models only anymore. They determine the ability of manufacturers to enable actual cybersecurity preparedness by testing, documenting, and assessing market risk.
That is why generic cybersecurity seller developers usually fail when the FDA conducts a review. The companies manufacturing medical devices require FDA medical device cybersecurity services that will help to fit the security testing into the financial reporting standards, quality systems, and submission dates. The lack of correspondence between technical results and documents that are ready to be presented to the FDA is often what causes the delays in the review, or new information requirements or further examination.
FDA Now Demands Faster, Risk-Based Security
The FDA expectations have also changed in the enforcement application. Late or less effective cybersecurity procedures, postmarket vulnerabilities, or sluggishness in responding to vulnerabilities or disclosed vulnerabilities have also led to safety communications, recalls, and regulatory follow-ups. Tools are no longer the key factor that assesses medical device cybersecurity companies in this context, but regulatory risk reduction capabilities and facilitating quicker approvals.
Currently, manufacturers are pressured to do it within a short period and comply at the same time. It is at this stage that senior partners contribute in a quantifiable way. This guide discusses what makes the greatest medical device cybersecurity firms, what the reviewers at the FDA really demand, and how manufacturers can identify the partners that will facilitate efficient design, shorter approval times, and adherence.
What Defines a Medical Device Cybersecurity Company for FDA Compliance
There are not all cybersecurity companies are ready to work with the FDA-regulated medical devices. FDA compliance makes vulnerabilities in addition to vulnerability finding. It requires technical expertise, understanding of regulatory requirements and documentation that is not readily available with many general security sellers.
The company that engages in qualified medical device cybersecurity is determined by the alignment of the activities in cybersecurity with what the FDA anticipates in the lifecycle of the devices.
The main features that support the differentiation of FDA-ready medical device security companies are:
- Security testing aligned with FDA: The security testing should be aligned with FDA medical device cybersecurity expectations, and not generic IT threat models. This involves the knowledge of the conversion of vulnerabilities into a risk to patient safety.
- Medical device penetration testing: A legitimate medical device penetration testing firm elevates the practice of automated scans to practical exploit paths of software, firmware, APIs, and network exposure of devices.
- Paperwork: FDA reviewers desire documentation of the first order. This will involve risk analyses, test procedures, analysis of results and justification of remediation, which is compatible with the FDA sub-mission structures.
- Assistance in pre and postmarket stages: FDA-backed medical device cybersecurity services are robust both in pre-market preparation and post market surveillance, where vulnerabilities are managed both before and after their approval.
- FDA history: A company that has a record of dealing with the FDA knows what to expect in terms of questions posed by the reviewer, areas of weakness, and how to operate within strict deadlines.
- Scalability to the complexity of the device: Starting with the startups in the early stages up to the enterprise OEMs, most medical device security companies are able to support the different architectures, connectivity models, and submission scopes.
Selecting a partner without FDA-specific expertise usually results in the wrong fit of technical results and regulatory expectations. This causes reworking, delays at submission and risk of additional enforcement.
Also Read: The Role of Penetration Testing in FDA 510(k) Compliance
Top Medical Device Cybersecurity Companies for FDA Compliance
According to the FDA expectations, adoption by the industry, and the list of requirements above evaluated, the organizations listed below are generally known as some of the most successful medical equipment cybersecurity firms in assisting with FDA compliance. This list is based on capability, regulatory match and practical application rather than claims made by the marketing side.
1. Qualysec
Best suited for: Best to Medical device startups, growth-stage companies and Fortune 500 manufacturers with a need to have responsible and FDA-aligned cybersecurity during the submission process through to approval.
Qualysec is not a typical medical device cybersecurity company. It functions as a unitary, responsible FDA cybersecurity collaborator, whereby it assists medical device manufacturers in both premarket and postmarket phases with a framework successfully tailored to meet the FDA reviewer expectations.
Since early start-up companies are preparing their initial FDA filing to large-scale manufacturers operating with complex product lines, Qualysec provides FDA penetration testing, risk validation, and documentation all under a unified set of processes. This removes the disintegration and delays that are usually brought about by a multi-vendor strategy.
What Makes Qualysec Different for FDA Compliance
The model by Qualysec is based on regulatory results and the reduction of risks, and not the output of security testing.
- The FDA penetration testing of any level, beginning with startup devices and enterprise platforms.
- Service support of urgent or time-bound filings by the FDA.
- Assured FDA-ready documentation conformed to the current FDA cybersecurity expectations.
- The engagement involved FDA approval support and not an addition.
- Free FDA compliance gap analysis to reveal risks before submission.
This will make sure that manufacturers do not have to coordinate with the security vendors, documentation consultants, and regulatory teams when the FDA is on the verge of major review periods.
100% FDA Approval Guarantee
We have a full-fledged end-to-end approach, which implies that we own the whole process.
Once you work through our entire framework, your cybersecurity documentation is up to the standards of the FDA.
This assurance is based on process ownership and not shortcuts. Within a single framework, Qualysec manages penetration testing, risk analysis, remediation validation, and FDA documentation to create consistency and regulatory alignment during the submission lifecycle.
Qualysec’s End-to-End FDA Cybersecurity Framework
In comparison to conventional medical device cybersecurity firms that have only provided isolated testing reports, Qualysec also offers a comprehensive FDA cybersecurity framework, which aligns technical validation with regulatory documentation.
What the framework includes:
- One partner all the way through.
- FDA documentation and technical security testing were a best match.
- Full responsibility: Qualysec is the owner of the work.
- Quick reaction of the FDA response without the involvement of a vendor.
- Documentation for FDA approval: all in-house.
Such a structure greatly decreases the submission friction, follow-up questions and FDA review cycles.
Proven FDA Track Record
The strategy of Qualysec is justified by the stable regulatory results.
Successful FDA experience of 20+ medical device submissions, enabled by an overarching cybersecurity architecture, which harmonizes testing, documentation, and regulatory requirements.
The manufacturers working with Qualysec enjoy better FDA communication, assertiveness of submissions, and fewer delays or enforcements are caused by cybersecurity issues.
Compliance Outcomes in Practice
Before Qualysec:
- Disjointed penetration testing and documentation.
- Weak mapping of patient safety impact and vulnerabilities.
- FDA follow-up interrogatives and protracted evaluation periods.
After Qualysec:
- Penetration testing is associated with exploit paths that are validated by the FDA.
- Baseless, verifiable cybersecurity records.
- More rapid review process and better regulatory confidence.
Why Qualysec Is the Safest Choice for FDA Cybersecurity
Qualysec is unique among cybersecurity firms in the medical device sector in that it has integrated:
- FDA penetration testing
- Security assessment services of medical devices.
- FDA documentation support
- Accountability and regulatory ownership.
Under one result-driven framework that is aimed at supporting patient safety and FDA compliance.
Call Qualysec today to ensure that your medical device meets safety and regulatory standards when entering the U.S. market.
2. NCC Group
Best suited for: Large companies with multi-faceted international portfolios and well-established internal regulators.
NCC Group is an experienced and long-standing cybersecurity consultancy that applies to regulated industries such as medical devices. Its FDA medical device cybersecurity practices are generally based on penetration testing, threat modeling and security advisory to the regulatory expectation. Large manufacturers who already have internal quality and regulatory infrastructure are often involved with NCC Group.
Strengths
- Well-developed experience in advanced testing of penetration and threat modeling.
- A long history of engagement in extremely controlled, international companies.
- Given the regional support capabilities of large and complex device ecosystems.
Limitations
- The engagements typically involve the coordination of various teams of NCC Group.
- FDA documentation convergence can require extra internal work on the part of manufacturers.
- Less focus on end-to-end ownership of submission preparedness.
3. UL Solutions
Best suited for: Organizations driven by compliance that have the need to have standards compatibility and certification.
UL Solutions has a rich experience in the area of safety, certification and regulatory testing. Medical device cybersecurity UL is also in the practice of placing a great emphasis on standards-related and regulatory-based assessments as opposed to adversarial tests. Manufacturers that focus more on formal validation of compliance than exploit-based testing also tend to use it.
Strengths
- Good reputation for safety and compliance validation.
- Knowledge of regulatory systems and certification procedures.
- Religiated brand in audit and standards-based examination.
Limitations
- More rule-abiding than rule-approving.
- Shallowness of adversarial penetration testing.
- Falling short in discussing FDA expectations on real-world exploitability.
4. MedSec (by Claroty)
Best suited for: Manufacturers of connected and IoMT-heavy medical devices
MedSec focuses on related medical device security, and it has a keen interest in embedded systems, as well as at the device-level. It is frequently utilised in intricate technical software examination of software, protocols, and IoMT exposure. MedSec is generally used to supplement larger FDA cybersecurity activities, and not to substitute complete submission processes.
Strengths
- Extensive understanding of embedded systems and device firmware security.
- Well-developed research skills in IoMT and connected risk devices.
- Important information on the device-specific attack surfaces.
Limitations
- Poor reporting of FDA records and filing procedures.
- In many cases necessitates the use of regulatory or documentation partners.
- More research-oriented than approval-oriented.
5. Cybellum
Best suited for: Manufacturers specializing in SBOM management and software supply chain visibility.
Cybellum focuses its services on the software bill of materials analysis and vulnerability intelligence. It is usually employed to aid post-market monitoring and third-party risk visibility, particularly in devices with complicated software dependencies.
Strengths
- Good SBOM and third-party visibility
- Idle in continuous vulnerability intelligence and postmarketing surveillance.
- Promotes FDA anticipations with regard to software transparency.
Limitations
- Weak penetration testing and exploit validation.
- Replaces neither adversarial testing nor patient safety risk validation.
- Needs more security testing services on FDA submissions.
6. Synopsys Software Integrity Group
Best suited for: Organizations that have security being integrated into the development and premarket processes.
Synopsys offers tooling and consulting services in relation to secure software development, static analysis, and dynamic testing. It is frequently employed at a prior point in the device lifecycle in order to enhance code quality and security hygiene.
Strengths
- Good dynamic and static application security testing.
- Incorporation in development pipelines and SDLC.
- Applicable in enhancing the premarket security posture.
Limitations
- The regulatory expertise required in developing FDA submission documentation is usually distinct.
- More tool-oriented than result-oriented.
- Lack of ownership of after-market cybersecurity processes.
7. Bishop Fox
Best suited for: Manufacturers that require profound adversarial penetration testing.
Bishop Fox is also a well-known provider of offensive security and high-end penetration testing. It is usually contracted in the medical device case scenario, where high-risk testing is involved, in which exploit verification becomes central.
Strengths
- Well-trained offensive security force.
- High exploit validation and testing capabilities.
- Useful in the discovery of complex attack paths.
Limitations
- Lack of concentration on FDA documentation and alignment with submissions.
- Normally needs supplementary partners in regulatory preparedness.
- Purchasing is not intended to possess end-to-end FDA cybersecurity procedures.
8. Secureworks
Best suited for: Enterprise settings with the integration of medical devices in the overall security processes.
Secureworks offers managed security services and monitoring that could be offered on a larger enterprise security program and help secure the medical devices environment.
Strengths
- Firm surveillance, identification, and reaction.
- Grows well in large enterprises.
- Helpful in the integration of operational security.
Limitations
- Lacks no expertise in FDA medical device submissions.
- Minor attention to risk validation of devices.
- Needs more cybersecurity partners that are FDA-oriented.
Avoid FDA Delays – Learn About FDA Agent Support.
9. IOActive
Best suited for: Assessment of embedded and hardware-intensive devices with heavy research.
IOActive deals with in-depth technical verification of hardware, firmware and embedded systems. It is used generally to conduct research-intensive security testing of critical device parts.
Strengths
- Sound experience in embedded systems and firmware testing.
- Intensive technical research skills.
- Applicable to complicated device designs.
Limitations
- Little emphasis on FDA documentation and lifecycle compliance.
- Frequently needs to liaise with regulatory experts.
- Not placed as a complete FDA compliance partner.
Recommended Read: A Complete Guide to FDA 510(k) Clearance
10. Atredis Partners
Best suited for: Specific testing of vulnerable machine parts.
Atredis Partners provides penetration testing of medical devices and embedded systems with a focus. Its work is commonly applied to legitimize certain areas of risk as opposed to comprehensive lifecycle cybersecurity programs.
Strengths
- It is highly technical in depth and assessment-oriented.
- Actionable and understandable technical reporting.
- Good at justifying particular security issues.
Limitations
- Inadequate guidance towards a complete FDA adherence lifecycle.
- Non-submission or postmarket workflow management was not in its design.
- Needs other partners in regulatory alignment.
How to Choose the Right Medical Device Cybersecurity Company for FDA Compliance
The choice of a medical device cybersecurity company is not a typical vendor. In the case of FDA-regulated products, the appropriate partner should support cybersecurity validation as well as regulatory preparedness throughout the lifecycle of the device.
In the assessment of medical device cybersecurity companies, manufacturers must consider the following.
FDA-Specific Cybersecurity Expertise
FDA medical device cybersecurity expectations are not known to all cybersecurity companies. An appropriate partner should have experience in:
- FDA premarket and postmarket cyberspace instructions.
- The translation of cybersecurity findings to the risk of patient safety.
- Popular FDA reviewer issues and lacks.
The experience of general IT or enterprise security is not sufficient to satisfy the FDA.
Ability to Validate Real-World Risk
Cybersecurity risk evaluation outside of theoretical frameworks is gaining more favor among FDA reviewers. An acceptable medical device penetration testing firm ought to:
- Authenticate vulnerability, not vulnerability listing.
- Test software, firmware, APIs, and update systems.
- Exposure to tests in realistic settings in the hospital or home.
The automated vulnerability scanning that lacks exploit validation cannot usually stand the scrutiny of the FDA.
Regulatory-Grade Documentation and Traceability
Poor documentation is one of the most prevalent issues in FDA reviews. The appropriate medical device security assessment services should offer:
- Evident connection of threats, vulnerabilities, mitigation and patient impact.
- The FDA provides ready-made filing templates that meet submission requirements.
- Paperwork that covers initial review and postmarket surveillance.
Security results that are not traceable to regulatory evidence prolong project timelines.
End-to-End Ownership and Accountability
Timelines of the FDA are usually tight and erratic. The process of involving multiple vendors to test, document, and remediate may result in gaps and delays. The most recommended cybersecurity companies in medical equipment:
- Own the entire process of cybersecurity.
- Conform to the results of testing with the FDA records.
- Minimize the risk of coordination in the submission and follow-up reviews.
Single-partner accountability has a strong effect on reducing the risk of approval.
Proven FDA Track Record
Experience in submitting to the FDA in the past. Business organizations that have an excellent track record with the FDA:
- Expect questions from the reviewer.
- Turnaround on requests for supplementary information is quicker.
- Minimize the chances of enforcement based on cybersecurity.
The demonstrated history is an excellent sign of dependability when it comes to regulatory pressure.
Common Mistakes Medical Device Manufacturers Make When Choosing a Cybersecurity Partner
Most of the FDA cybersecurity problems are not caused by the absence of testing, but by the incompatibility of the expectations between manufacturers and their security vendors. These are the common errors that result in either the delay of reviews, increased scrutiny or enforcement risk.
- Treating Postmarket Cybersecurity as Documentation Only: There are those manufacturers who perceive postmarket cybersecurity as a piece of paper. The expectations of the FDA, however, centrally revolve around the actual performance of the system, such as the ability to detect, evaluate and address vulnerabilities after implementation.
- Late Response to Announced Vulnerabilities: Delays in responding to vulnerability disclosures or responding non-systematically may result in FDA cybersecurity enforcement. Manufacturers should exhibit prompt assessment and corrective action in accordance with patient safety.
- Absence of Exploitability or Impact Validation: It is a failure point to base vulnerability scan results just on the results of vulnerability scans and not evaluate exploit paths. The reviewers at FDA are increasingly demanding evidence that risks have been considered in actual, adversarial conditions.
- Inadequate liaison between security and regulatory groups: As long as cybersecurity testing is not integrated with regulatory documents, discrepancies are found in submissions. This frequently leads to follow-ups, requests for additional evidence or long review periods.
- The assumption that Vulnerability Scanning Is Sufficient: Automated scanning tools come in handy; however, they do not sideline penetration testing or risk validation. Identified problems should be supported through how they impact safety and effectiveness, as opposed to severity scores, by FDA medical device cybersecurity services.
Key to averting such errors is the choice of the partner matching FDA requirements, engages in the ownership of the cybersecurity process and harmonizing technical discoveries and regulatory results.
Avoid These FDA Cybersecurity Pitfalls, Talk to an FDA Cybersecurity Expert.
FDA Cybersecurity Enforcement Trends and What They Signal to Manufacturers
The FDA enforcement of cybersecurity has become more obvious and more impactful on the medical device manufacturers, particularly as the devices are much more software-based and connected. Over the past few years, the FDA has shown a definite move towards advisory oversight, instead of active postmarket research, when the weaknesses of cybersecurity present potential hazards to the safety of the patient.
The method used by FDA to recognize postmarket cybersecurity problems is one of the strongest indicators. These problems may be evident in the form of organized vulnerability reports, postmarket surveillance reports, third-party research or even incident reports provided by health care providers. Failure to deal with the vulnerabilities in a systematic or timely way may lead to an escalation of the response to an informal announcement by the FDA.
Important enforcement indicators that should be observed by manufacturers are:
- Cybersecurity vulnerabilities that are not addressed or improperly handled and which might affect the safety or effectiveness of a device are prompted by safety communications and recalls.
- Letters of warning and inspection reports that identify gaps in the postmarket surveillance, vulnerability response procedures, or documentation on cybersecurity.
- Heightened security inspections of connected and software-based devices, especially those that are remotely accessed, have wireless connections, or cloud connections.
- Further investigations in case of evidence of slow remediation, flawed risk evaluation or inadequate links between security and quality systems.
The common trend in FDA cybersecurity implementation is that the problems are not usually caused by a single vulnerability. Rather, they are systemic failures that are caused by factors like a lack of monitoring, the absence of exploitability analysis, or a lack of connection between cybersecurity discoveries and patient safety impact. Manufacturers that are unable to prove a repeat, well-documented postmarket cybersecurity procedure tend to experience a lengthy regulatory contact.
To the manufacturers, the message is forthright. The FDA medical device cybersecurity is not only assessed once the clearance or approval takes place. The evidence of mature cybersecurity governance, postmarket performance, and responsiveness becomes more critical to the continued staying of an organization in good regulatory positions. Enforcement risk is now reduced through proactive postmarket surveillance, a validated risk assessment and prompt remediation.
Conclusion
The concern of cybersecurity of medical devices has become an essential regulation and patient safety mandate. With the increased demands of FDA requirements on design-time controls, but the realities of real-time performance, manufacturers have to make sure that their cybersecurity programs can endure both technical and regulatory inspections.
Tools cease to be the metric of the best medical device cybersecurity companies. They are characterized by their ability to justify actual risk, generate FDA-ready documentation, and support manufacturers throughout both premarket and postmarket stages without fragmentation or delays. Accountability and ownership of processes are more important than technical expertise in an environment where enforcement actions are more and more the result of postmarket failures.
Qualysec is founded on this fact. Nearly 20+ medical devices have relied on Qualysec to achieve successful FDA approvals with an end-to-end FDA cybersecurity framework, which integrates penetration testing, risk validation, and regulatory documentation on a single responsible partner. Since the support on emergency FDA submission to ensure FDA-ready documents is provided, protective regulatory risk and patient safety are the main priorities.
In case you have an FDA application in the pipeline, are faced with postmarket cybersecurity requirements, or need to reassess your existing security providers, it is best to take action before enforcement problems occur.
Get a Free FDA Compliance Gap Analysis with Qualysec and prepare FDA-ready cybersecurity documentation with confidence.
FAQs
Q: What do medical device cybersecurity companies do for FDA compliance?
A: Medical device cybersecurity firms assist manufacturers to identify, validate and reduce cybersecurity risks in accordance with the FDA medical device cybersecurity expectations. Their services usually involve penetration testing, risk assessment and FDA-ready documentation, which portrays patient safety and regulatory preparedness.
Q: How are medical device cybersecurity companies different from general security vendors?
A: Compared to general cybersecurity companies, the medical device cybersecurity companies are aware of the FDA cybersecurity requirements and the translation of security findings into patient safety risk. They not only compare the results of testing with the regulatory documentation and FDA submission expectations, but also with technical vulnerability lists.
Q: Does the FDA require manufacturers to work with a medical device penetration testing company?
A: There is no vendor that FDA requires, but it anticipates manufacturers to test cybersecurity threats outside automated scans. Engaging a certified medical device penetration testing firm can assist in proving the in-practice exploitability and FDA reviews of medical device cybersecurity.
Q: Can vulnerability scanning alone satisfy FDA cybersecurity expectations?
A: No. Automated vulnerability testing will be helpful in the detection of problems, but FDA auditors are placing more demands on the validation of the exploits and risk explanation. Cybersecurity medical device firms need to demonstrate the potential vulnerabilities to compromise the safety and usefulness of devices in actual contexts.
Q: When should manufacturers engage medical device cybersecurity companies?
A: The manufacturers are supposed to participate in the early stages of development until the postmarket stages. The continued cooperation facilitates FDA clearance, post-market surveillance and prompt reaction to cybersecurity threats.
Q: Why is penetration testing important for FDA medical device cybersecurity?
A: Penetration testing proves the fact that vulnerabilities are realistically exploitable in deployed medical devices. This will assist manufacturers to prove that the risks of cybersecurity have been evaluated not only in the area of patient safety but also in the area of theoretical severity.
0 Comments